StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CCRN$13.09+0.00%
Fair $13.09+0.0%

CCRN

Cross Country Healthcare, Inc.

Healthcare / Medical Care FacilitiesNasdaqGS

$13.09

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $13.09Fund rank 25/100 · Data gapFallback financials|
SA 30/D
F-Score: 4/9
Declining RevenueMargin CompressionLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $111.4M · quality 43.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 12/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

30/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 17Warnings: 3unknown: 17
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years Operating margin has declined for 3 consecutive years ROE is -29.4%, below the 5% threshold
Thesis & Journal · CCRNLocal privado en este navegador · Cross Country Healthcare, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$406M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-29.4%

↓

Gross Margin

20.3%

↓

Debt/Equity

0.01

↓
52-Week Range$13
$7$15

TradingView lightweight chart

CCRN price, volumen y niveles de valoración

Último $13.09Periodo -35.7%
Fair value: $13.09

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2009–2025 · 16 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

3.8%

FCF / Net income

-0.42x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.05B · net income $-94.9M · FCF $40.1M

2009-FY → 2025-FY

Gross margin

20.3%— pts

Operating margin

-0.4%— pts

Net margin

-9.0%— pts

FCF margin

3.8%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Income Statement
Revenue$1.05B$1.05B$1.34B$2.02B$2.80B$1.68B$836.4M$822.2M$816.5M$865.0M$833.5M———————
Net Income$-94.9M$-94.9M$-14.6M$72.6M$186.0M$132.0M$-13.0M$-57.7M$-17.0M$37.5M$8.0M$4.4M$-31.8M$-52.0M$-42.2M$4.1M$-2.8M$6.7M
EBITDA$-64.5M$-64.5M$4.0M$129.3M$280.1M$149.2M$3.5M$-1.6M$-1.1M$21.9M$15.4M$28.6M$-3.0M—————
EPS-2.93-2.93-0.442.055.023.53-0.36-1.61-0.481.010.150.14-1.02-1.68-1.370.13-0.090.22
Gross Margin20.3%20.3%20.4%22.3%22.3%—————————————
Operating Margin-0.4%-0.4%1.7%6.5%10.3%8.3%-1.1%-1.9%-1.6%1.4%0.7%———————
Net Margin-9.0%-9.0%-1.1%3.6%6.6%7.9%-1.5%-7.0%-2.1%4.3%1.0%———————
Balance Sheet
Debt/Equity0.010.010.010.010.350.620.360.440.360.390.56———————
Current Ratio3.293.29————————————————
Cash Flow
Free Cash Flow$40.1M$40.1M$111.4M$234.5M$125.3M$-92.8M$22.6M$2.6M$16.4M$40.4M$23.6M$15.9M$-8.6M$6.9M$7.9M$14.3M$29.1M—
Returns
ROE-29.4%-29.4%-3.5%15.5%40.7%44.9%-8.4%-35.5%-7.8%15.8%5.3%3.1%-24.5%-32.3%-20.2%1.6%-1.1%2.7%
Valuation
P/E———11.095.71—————————————
EV/EBITDA——132.856.144.39—————————————
P/B1.311.311.451.722.35—————————————
Growth & Yield
Revenue Growth-21.6%-21.6%-33.5%-28.0%—100.5%1.7%0.7%-5.6%3.8%————————
EPS Growth-565.9%-565.9%-121.5%-59.2%—1080.6%77.6%-235.4%-147.5%573.3%7.1%113.7%39.3%-22.6%-1153.8%244.4%-140.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -0.7%

Total return

-0.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.44 → -2.93

Residual

-0.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-0.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.